Categories: NewsPatient Care

Doheny Eye Institute Welcomes Emma Lessieur-Contreras, MD, PhD, as Principal Investigator

Dr. Lessieur-Contreras will continue her groundbreaking research on understanding the early stages of diabetic retinopathy

Emma Lessieur-Contreras, MD, PhD

Doheny Eye Institute Welcomes Emma Lessieur-Contreras, MD, PhD, as Principal Investigator

PASADENA, Calif., June 05, 2025 (GLOBE NEWSWIRE) — Doheny Eye Institute, one of the nation’s leading vision research institutions for more than 75 years, is adding to its panel of remarkable vision scientists with the appointment of Emma Lessieur-Contreras, MD, PhD, as Principal Investigator. Dr. Lessieur-Contreras also will be a faculty member in the UCLA Department of Ophthalmology as an Assistant Professor-in-Residence.

“Dr. Lessieur-Contreras is pursuing compelling research that will complement and help propel Doheny Eye Institute’s work on diabetic retinopathy even further,” said Deborah Ferrington, PhD, Chief Scientific Officer of Doheny Eye Institute. “Doheny’s commitment to groundbreaking vision research is second to none, and we look forward to seeing what Dr. Lessieur-Contreras will achieve as part of our team.”

Dr. Lessieur-Contreras earned her medical degree from the Universidad Autónoma de Tamaulipas in Mexico and completed her PhD in Molecular Medicine at Case Western Reserve University. Her research journey spans from exploring retinal genetics and photoreceptor function in zebrafish models to impactful work in diabetic retinopathy. Most recently, during her postdoctoral training at the University of California, Irvine under Dr. Timothy Kern, she investigated how extracellular vesicles mediate immune signaling in the early stages of diabetic retinopathy.

“Doheny Eye Institute is a highly respected beacon of research excellence, and I am eager to continue my research on diabetic retinopathy alongside experts in this field,” said Dr. Lessieur-Contreras. “The state-of-the-art research facilities at Doheny’s Pasadena campus, coupled with its visionary leaders, create the setting and opportunities to think bigger, collaborate and push forward innovative new approaches to vision science.”

The pioneering work conducted by Dr. Lessieur-Contreras is supported by a prestigious K99/R00 MOSAIC Career Transition Award from the National Eye Institute.

For more information about the groundbreaking vision research that takes place every day at Doheny Eye Institute, visit www.doheny.org.

About Doheny Eye Institute
Doheny Eye Institute is one of the nation’s leading vision research institutions with a history dating back over 75 years. Doheny scientists and clinician-scientists remain at the forefront of vision science investigating how retinal cells function in health and in diseases, such as diabetic retinopathy, optic neuropathies, uveitis, and age-related macular degeneration, and using artificial intelligence for improved diagnosis of ocular diseases.

Since 2013, the Doheny and UCLA Stein Eye Institute affiliation combines the strength, reputation, and distinction of two of the nation’s top eye institutions to advance vision research, education, and patient care in Southern California. Together, Doheny Eye Institute and UCLA Stein Eye Institute are ranked in the Top 5 vision centers in the country by U.S. News & World Report.

For more information visit www.Doheny.org.

Contact:
Molly Ann Woods
Doheny Eye Institute
310-717-0955
mwoods@doheny.org

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/aeea71f5-245d-4c3d-b8de-29d9b18fd664


Staff

Recent Posts

World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors

Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates…

2 hours ago

CelLBxHealth PLC – Aligning Regulatory Approach with Commercial Needs

CelLBxHealth strengthens cost discipline by aligning FDA regulatory approach with current commercial needs GUILDFORD, SURREY…

5 hours ago

UTulsa’s Hurricane Ventures announces investment in BioReact

TULSA, Okla., Feb. 12, 2026 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have…

14 hours ago

BioMarin Announces Closing of Private Offering of Senior Notes

SAN RAFAEL, Calif., Feb. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced…

14 hours ago

10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in…

14 hours ago

US Signal Expands OpenCloud with Services Designed for Greater Flexibility and Platform Choice

Expanded OpenCloud services deliver secure desktops and workload mobility with predictable economics and greater control.GRAND…

14 hours ago